Literature DB >> 25995001

Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.

Kenji Ishitsuka1, Mutsunori Murahashi2, Hiroo Katsuya2, Ai Mogi2, Michio Masaki2, Chisato Kawai2, Toshitaka Goto2, Masanao Ishizu2, Yosuke Ikari2, Yasushi Takamatsu2, Hideki Ishibashi3, Satoshi Nimura4, Morishige Takeshita4, Kazuo Tamura2.   

Abstract

A 57-year-old male with acute-type adult T cell leukemia-lymphoma (ATL) developed persistent watery, non-bloody diarrhea at a volume of 2-3 L/day following the administration of the anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, mogamulizumab. An extensive examination revealed the absence of any pathogenic bacteria or parasites in his stool. Biopsied specimens from the colonic mucosa contained many small nests of apoptotic bodies in the colonic glands, which mimicked acute-colonic graft-versus-host disease. Activation of the auto-reactive immune system due to the depletion of regulatory T-cells by mogamulizumab was suspected as causative. Special attention should be paid to the risk of unique immune-related adverse events induced by mogamulizumab.

Entities:  

Keywords:  Adult T-cell lymphoma/leukemia; CCR4; Colitis; Immune-related adverse event; Mogamulizumab

Mesh:

Substances:

Year:  2015        PMID: 25995001     DOI: 10.1007/s12185-015-1811-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

2.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

Authors:  S Wilgenhof; B Neyns
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.

Authors:  Hiroo Katsuya; Takeharu Yamanaka; Kenji Ishitsuka; Atae Utsunomiya; Hidenori Sasaki; Shuichi Hanada; Tetsuya Eto; Yukiyoshi Moriuchi; Yoshio Saburi; Masaharu Miyahara; Eisaburo Sueoka; Naokuni Uike; Shinichiro Yoshida; Kiyoshi Yamashita; Kunihiro Tsukasaki; Hitoshi Suzushima; Yuju Ohno; Hitoshi Matsuoka; Tatsuro Jo; Junji Suzumiya; Kazuo Tamura
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

5.  The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.

Authors:  Toyohide Shinkawa; Kazuyasu Nakamura; Naoko Yamane; Emi Shoji-Hosaka; Yutaka Kanda; Mikiko Sakurada; Kazuhisa Uchida; Hideharu Anazawa; Mitsuo Satoh; Motoo Yamasaki; Nobuo Hanai; Kenya Shitara
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

6.  Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

Authors:  Toshihiko Ishii; Takashi Ishida; Atae Utsunomiya; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Kazunori Imada; Takashi Uchiyama; Shiro Akinaga; Kenya Shitara; Ryuzo Ueda
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

7.  Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.

Authors:  Koji Kato; Toshihiro Miyamoto; Akihiko Numata; Takashi Nakaike; Hideyo Oka; Ayano Yurino; Takuro Kuriyama; Yasuo Mori; Satoshi Yamasaki; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-02-09       Impact factor: 2.490

8.  Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.

Authors:  Takashi Ishida; Asahi Ito; Fumihiko Sato; Shigeru Kusumoto; Shinsuke Iida; Hiroshi Inagaki; Akimichi Morita; Shiro Akinaga; Ryuzo Ueda
Journal:  Cancer Sci       Date:  2013-03-10       Impact factor: 6.716

Review 9.  Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.

Authors:  Kenji Ishitsuka; Kazuo Tamura
Journal:  Lancet Oncol       Date:  2014-10       Impact factor: 41.316

10.  Severe meningo-radiculo-neuritis associated with ipilimumab.

Authors:  Flavie Bompaire; Christine Mateus; Hervé Taillia; Thierry De Greslan; Marion Lahutte; Magali Sallansonnet-Froment; Madani Ouologuem; Jean-Luc Renard; Guy Gorochov; Caroline Robert; Damien Ricard
Journal:  Invest New Drugs       Date:  2012-01-11       Impact factor: 3.651

View more
  5 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 2.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 3.  Recent Advances in Therapeutic Approaches for Adult T-cell Leukemia/Lymphoma.

Authors:  Koji Kato; Koichi Akashi
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048

4.  Multi-omic analysis of signalling factors in inflammatory comorbidities.

Authors:  Hui Xiao; Krzysztof Bartoszek; Pietro Lio'
Journal:  BMC Bioinformatics       Date:  2018-11-30       Impact factor: 3.169

5.  Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-cell lymphoma.

Authors:  Ishan Asokan; Sanminder Singh; John Moesch; Jonhan Ho; Oleg E Akilov
Journal:  JAAD Case Rep       Date:  2021-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.